AstraZeneca put the rest of the SGLT2 inhibitor class on notice when its Farxiga scored an FDA heart failure nod in patients with or without diabetes. One of its competitors, Eli Lilly and Boehringer Ingelheim’s Jardiance, is fast on Farxiga’s heels, though, and it’s ready to bring its pivotal trial win in front of physicians. Jardiance, added… Read More »
Bob Harper is back again in AstraZeneca’s cardiac survivor awareness effort. AZ re-signed the fitness guru and TV personality, who famously survived a near-fatal heart attack in 2017, for the third year of their joint “Survivors Have Heart” campaign. Harper also stars in AstraZeneca’s DTC campaign for blood thinner Brilinta, including a TV ad where he talks… Read More »
Heart disease can include several problems related to the heart and blood vessels, many of which are related to atherosclerosis. A buildup of plaque in the walls of the arteries makes it difficult for blood flow, which can lead to a heart attack or stroke. In 2017, 859,125 deaths in the U.S. were attributed to… Read More »